| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
Date of Report (Date of Earliest Event Reported): November 16, 2026 |
| 05 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
CREDIT AGREEMENT, dated as of November 4, 2026, by and among ANI PHARMACEUTICALS, Inc., a Delaware corporation (the “Lead Borrower”), the Additional Subsidiary Borrowers (as hereinafter defined), the Guarantors (as hereinafter defined), ... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
PRINCETON, N.J., November 5, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026. |
| 24 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
PRINCETON, N.J., August 7, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026. |
| 21 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (this “Plan”) is to advance the interests of ANI Pharmaceuticals, Inc. (the “Company”) and its stockholders by enabling the Company and its Subsi... |
| 13 May 2026 |
8-K: Regulation FD Disclosure
© 2026 ANI Pharmaceuticals, Inc. 1 Corporate Presentation May 2026 |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
PRINCETON, N.J., May 8, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2026. |
| 07 Apr 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated April 7, 2026 of ANI Pharmaceuticals, Inc. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the reg... |
| 03 Mar 2026 |
8-K: Regulation FD Disclosure
© 2026 ANI Pharmaceuticals, Inc. 1 Corporate Presentation March 2026 |
| 27 Feb 2026 |
8-K: Results of Operations and Financial Condition
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
© 2026 ANI Pharmaceuticals, Inc. 1 Corporate Presentation January 2026 |
| 01 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Patrick D. Walsh steps down as Chairman and will complete his current term as Board member |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
© 2025 ANI Pharmaceuticals, Inc. 1 Corporate Presentation November 2025 |
| 07 Nov 2025 |
8-K: Results of Operations and Financial Condition
PRINCETON, N.J., November 7, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2025. |
| 26 Sep 2025 | 8-K: Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders |
| 08 Sep 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
© 2025 ANI Pharmaceuticals, Inc. 1 Corporate Presentation September 2025 |
| 08 Aug 2025 |
8-K: Results of Operations and Financial Condition
BAUDETTE, Minn., August 8, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2025. |
| 29 Jul 2025 |
8-K: Other Events
On March 4, 2024, ANI Pharmaceuticals, Inc. (the “Company”) commenced a civil action against CG Oncology, Inc. f/k/a Cold Genesys, Inc. (“CG Oncology”) in the Superior Court of the State of Delaware. The Company’s complaint alleges that,... |
| 23 Jul 2025 |
8-K: Other Events
Disclaimers 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about our exp... |
Loading...